8th Sep 2014 07:05
LONDON (Alliance News) - AstraZeneca PLC said Monday that safety and efficacy data from its Phase IIa study of benralizumab for the treatment of chronic obstructive pulmonary disease were published in 'The Lancet Respiratory Medicine' medical journal.
The study did not meet its primary endpoint, as benralizumab did not reduce the acute exacerbation rate compared with a placebo in the overall patient population. However, it did show "clinically significant improvements in lung function" in the overall population.
Additionally, it showed that it reduced chronic obstructive pulmonary exacerbations and improved other symptoms of the disease in certain patient groups.
The study data will also be presented at the 2014 European Respiratory Society International Congress in Munich, Germany, along with other data from the company's respiratory portfolio.
Shares in AstraZeneca were trading down 0.8% at 4,517.50 pence Monday morning, shortly after market open.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca